论文部分内容阅读
目的探讨贝那普利联合缬沙坦治疗糖尿病肾病患者的临床疗效。方法选取2015年3月至2016年5月山东省东营乐安糖尿病肾病医院收治的180例糖尿病肾病患者作为研究对象,根据随机化分组原则分为对照组1(60例)、对照组2(60例)和观察组(60例)。对照组1患者采用贝那普利进行治疗,对照组2患者给予缬沙坦,观察组患者则联合使用以上两种药物,比较3组患者治疗后的总有效率、24 h尿蛋白、尿素氮、血肌酐、空腹血糖。结果观察组患者治疗的总有效率明显高于对照组1和对照组2,3组患者治疗后的24 h尿蛋白、尿素氮、血肌酐、空腹血糖均显著优于治疗前,但观察组患者的24 h尿蛋白改善程度显著优于对照1、2组,差异均有统计学意义(均P<0.05)。结论在糖尿病肾病患者的治疗过程中,采用贝那普利联合缬沙坦治疗能够使患者获得更佳疗效,并能显著降低尿蛋白,延缓疾病进展,改善患者预后。
Objective To investigate the clinical efficacy of benazepril combined with valsartan in the treatment of diabetic nephropathy. Methods A total of 180 patients with diabetic nephropathy were enrolled in the Le Ann Diabetic Nephropathy Hospital of Dongying City, Shandong Province from March 2015 to May 2016. The patients were divided into control group (60 cases), control group (60 cases) and control group (60 cases) Cases) and observation group (60 cases). The patients in control group 1 were treated with benazepril, the patients in control group 2 were given valsartan, and the patients in observation group were combined with the above two drugs. The total effective rate, 24-hour urine protein and urea nitrogen , Serum creatinine, fasting blood sugar. Results The total effective rate of treatment in observation group was significantly higher than that in control group 1 and control group 2, 3 groups after 24 hours of treatment, urinary protein, urea nitrogen, serum creatinine, fasting blood glucose were significantly better than before treatment, but the observation group 24 h urinary protein improved significantly better than the control group 1,2 group, the difference was statistically significant (P <0.05). Conclusion In the course of treatment of patients with diabetic nephropathy, the combination of benazepril and valsartan can achieve better therapeutic effect, reduce the proteinuria, delay the progression of the disease and improve the prognosis of patients.